SIM
BCLI

Spark Investment Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Spark Investment Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-800
Closed -$55K – 105
2020
Q1 		$55K Buy
+800
New +$62.4K 0.03% 314
2015
Q2 		– Sell
-3,947
Closed -$262K – 665
2015
Q1 		$262K Buy
3,947
+1,494
+61% +$94.5K 0.04% 493
2014
Q4 		$175K Buy
+2,453
New +$129K 0.03% 511

Other funds holding BCLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Spark Investment Management's BCLI Position: Q2 2020 in Review

Spark Investment Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2020, closing a stake of 800 shares — an estimated $55K sold.

Spark Investment Management first reported a position in BCLI in Q4 2014 and held it in 3 quarters. The position peaked at $262K in Q1 2015. 76 funds tracked by Wall St. Rank hold BCLI as of Q2 2020.

  • Spark Investment Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2020 after selling out during the quarter.
  • Spark Investment Management sold 800 BRAINSTORM CELL THERAPUTC shares in Q2 2020, an estimated $55K.
  • Spark Investment Management first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2014 and held it in 3 quarters.
  • Spark Investment Management's BRAINSTORM CELL THERAPUTC position peaked at $262K in Q1 2015.
  • 76 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.